home / stock / mrkr / mrkr news

MRKR News and Press, Marker Therapeutics Inc. From 07/31/23

Stock Information
Company Name: Marker Therapeutics Inc.
Stock Symbol: MRKR
Market: NASDAQ
Website: markertherapeutics.com
Menu
MRKR MRKR Quote MRKR Short MRKR News MRKR Articles MRKR Message Board
Get MRKR Alerts

News, Short Squeeze, Breakout and More Instantly...
MRKR - MNK, GDRX and MRKR among mid-day movers

2023-07-31 13:08:57 ET Gainers: Mallinckrodt ( MNK ) +42% . Fifth Wall Acquisition Corp. III ( FWAC ) +40% . Tupperware Brands Corporation ( TUP ) +40% . GoodRx Holdings ( GDRX ) +37% . Archer Aviation ( ACHR ) +36% . Steakho...
MRKR - MRKR, VIEW and ICLK among mid-day movers

2023-07-28 12:49:57 ET Gainers: Unique Fabricating ( UFAB ) +74% . Reata Pharmaceuticals ( RETA ) +52% . INVO Bioscience ( INVO ) +45% . Bluejay Diagnostics ( BJDX ) +44% . View ( VIEW ) +40% . iClick Interactive Asia Group L...

MRKR - Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023

HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced participat...

MRKR - Marker Therapeutics Inc. (NASDAQ: MRKR) Near the Top of Equities by Percentage Gain on 7/24

Marker Therapeutics, Inc. (NASDAQ: MRKR) is one of today's top gainers. The company's shares are currently up 18.53% on the day to $7.83. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapie...
MRKR - TTOO, ALPP and MRKR among mid-day movers

2023-07-10 12:50:24 ET Gainers: Prestige Wealth ( PWM ) +39% . Nanobiotix S.A. ( NBTX ) +37% . Gorilla Technology Group ( GRRR ) +35% . NanoString Technologies ( NSTG ) +34% . Sientra ( SIEN ) +31% . T2 Biosystems ( TTOO ...

MRKR - European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced that zedenoleu...

MRKR - Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, to...
MRKR - MRKR, TMC and SIEN among mid-day movers

2023-06-16 14:00:02 ET Gainers: Evelo Biosciences ( EVLO ) +120% . Sientra ( SIEN ) +29% . TMC the metals company ( TMC ) +24% . ICZOOM Group ( IZM ) +20% . iRobot Corporation ( IRBT ) +20% . Marker Therapeutics ( MRKR ) ...

MRKR - First Wave, YS Biopharma top healthcare gainers; Jin Medical, Finch Therapeutics among losers

2023-06-13 10:10:06 ET Gainers: First Wave BioPharma ( FWBI ) +150% . YS Biopharma ( YS ) +20% . Akoya Biosciences ( AKYA ) +17% . Evoke Pharma ( EVOK ) +16% . Surmodics ( SRDX ) +16% . Losers: Jin Medical International ( ...

MRKR - Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

HOUSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that t...
Previous 10 Next 10